Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
I went to Japan during peak cherry blossom season and found an easy way to escape the crowds at popular tourist attractions - 2Figure out How to Score Huge with Open Record Rewards
- 3Watching ‘Home Alone’ with the kids this holiday season? Brace yourself for '6-7.'
- 4Taylor Frankie Paul's domestic violence case is fueling discussions about DARVO. Experts say terms like this shouldn't be used lightly.
- 5These are the Fastest Italian Sports Cars
- Zelensky confidant dismissed from further posts amid bribery scandal
- The most effective method to Redesign the Sound Framework in Your Smash 1500.
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- Bavarian leader questions Germany's Eurovision participation
- NASA's SPHEREx telescope completes its 1st cosmic map of the entire sky and it's stunning!
- The most effective method to Recognize an Excellent Lab Precious stone
- Flu season is ramping up, and some experts are "pretty worried"
- 5 Chiefs That Changed Our Opinion on Film
- Before trips to Mars, we need better protection from cosmic rays
